News stories about Athersys (NASDAQ:ATHX) have been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Athersys earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.3792525061385 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern’s scoring:
- Japanese study involving Athersys’ MultiStem technology has enrolled its first patient – Crain’s Cleveland Business (crainscleveland.com)
- HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic Stroke (finance.yahoo.com)
- Brokerages Set $12.00 Price Target for Athersys, Inc. (ATHX) (americanbankingnews.com)
- Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target (americanbankingnews.com)
ATHX has been the subject of a number of recent research reports. Maxim Group reiterated a “buy” rating and issued a $12.00 target price on shares of Athersys in a report on Friday, September 1st. Zacks Investment Research upgraded Athersys from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Tuesday, August 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.17.
In other news, EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $2.17, for a total value of $32,550.00. Following the completion of the transaction, the executive vice president now owns 679,416 shares in the company, valued at approximately $1,474,332.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.40% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Athersys (ATHX) Receiving Somewhat Positive News Coverage, Accern Reports” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/19/athersys-athx-receiving-somewhat-positive-news-coverage-accern-reports.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.